Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sukhvinder Johal

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
BMC Ophthalmology|June 4, 2015
Mydriasert pupillary dilation for cataract surgery: an economic and clinical studyAmeet Shah, Sukhvinder Johal, Nicholas Lee
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2013
Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysisSukhvinder Johal, Stephen Ralston, Christopher Knight
Journal of Market Access & Health Policy|October 27, 2025
EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-MakingAdam Johns, André Andrade, Sukhvinder Johal, et al.
Experimental Hematology & Oncology|February 20, 2018
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United StatesCharles McCrea, Sukhvinder Johal, Shuo Yang, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 4, 2024
Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case StudySukhvinder Johal, Lance Brannman, Victor Genestier, et al.
Infection|April 11, 2016
A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyMaureen Watt, Charles McCrea, Sukhvinder Johal, et al.
Journal of Comparative Effectiveness Research|May 22, 2026
Estimating the societal impact of medical interventions: a case study in metastatic breast cancerFoteini Tsotra, Kyle Dunton, Mats Rosenlund, et al.
Pharmacoeconomics|November 20, 2019
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival OutcomesCaitlin Smare, Khalid Lakhdari, Justin Doan, et al.
Journal of Thoracic Disease|July 19, 2021
Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature reviewSukhvinder Johal, Robert Hettle, Joe Carroll, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor PrognosisEvo Alemao, Sukhvinder Johal, Maiwenn J Al, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
BMC Ophthalmology|June 4, 2015
Mydriasert pupillary dilation for cataract surgery: an economic and clinical studyAmeet Shah, Sukhvinder Johal, Nicholas Lee
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2013
Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysisSukhvinder Johal, Stephen Ralston, Christopher Knight
Journal of Market Access & Health Policy|October 27, 2025
EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-MakingAdam Johns, André Andrade, Sukhvinder Johal, et al.
Experimental Hematology & Oncology|February 20, 2018
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United StatesCharles McCrea, Sukhvinder Johal, Shuo Yang, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 4, 2024
Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case StudySukhvinder Johal, Lance Brannman, Victor Genestier, et al.
Infection|April 11, 2016
A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyMaureen Watt, Charles McCrea, Sukhvinder Johal, et al.
Journal of Comparative Effectiveness Research|May 22, 2026
Estimating the societal impact of medical interventions: a case study in metastatic breast cancerFoteini Tsotra, Kyle Dunton, Mats Rosenlund, et al.
Pharmacoeconomics|November 20, 2019
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival OutcomesCaitlin Smare, Khalid Lakhdari, Justin Doan, et al.
Journal of Thoracic Disease|July 19, 2021
Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature reviewSukhvinder Johal, Robert Hettle, Joe Carroll, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor PrognosisEvo Alemao, Sukhvinder Johal, Maiwenn J Al, et al.
Pageof 2